Connor Iapoce

New, 2-year results from the phase 3 PHOTON study show continued benefit for patients with diabetic macular edema treated with aflibercept 8mg.

The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

12-month GATHER2 results show monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth than sham treatment.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

Most answers provided by ChatGPT-4 were consistently appropriate regarding vitreoretinal surgeries, including retinal detachments, macular holes, and epiretinal membranes.

A deep learning system using ultra-widefield fundus imaging exhibited relatively good performance in detecting 5 common retinal lesions in rural areas.

Utilizing swept-source OCT, the analysis reports significantly thicker subfoveal choroidal thickness among patients with active disease than those with inactive disease.

The post-hoc analysis of a phase 3 clinical trial suggests SB15 has comparable clinical efficacy and safety to aflibercept in patients with nAMD.

Patients with UC and Crohn's disease showed higher drug levels and good acceptance when switching from intravitreal to subcutaneous infliximab.

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial.

In a new study, upper endoscopy identified the cause of iron deficiency anemia in more than 70% of children.

A large pediatric study suggests the diagnostic marker is both reliable and practical with high sensitivity and acceptable specificity for identifying iron deficiency and iron deficiency anemia.

The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins.

Individuals in racial and ethnic minority groups and those with lower socioeconomic status were less likely to consent to participate in ophthalmic clinical studies.

The expanded Indication now includes children of all ages with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature.

24-month results from OAKS and DERBY show that pegcetacoplan significantly reduced GA lesion growth with both monthly and every-other-month dosing.

A convolutional neural network accurately predicted eyes that progressed from intermediate AMD to GA within 1 year using volumetric SD-OCT scans.

Although both anti-VEGFs maintain a consistent safety profile, aflibercept shows a more pronounced short-term inhibitory effect on inflammation after vitrectomy for diabetic retinopathy.

New cross-sectional research indicates factors influencing ocular lesion status can include diabetes status, prednisolone dosage, and systemic infection status after kidney transplantation.

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

Adolescents from socioeconomically disadvantaged backgrounds were less likely to report receiving a vision test, particularly in clinical settings.

Racial and ethnic disparities in ocular comorbidities significantly contributed to US deaths from 2000 to 2019, particularly among American Indian or Alaska Native and Hispanic individuals.